Systemization is key to fulfilling T cell therapy’s promise in cancer

Whilst first generation CAR-T therapies have already transformed cancer treatments, fundamental barriers remain in translating the treatment’s success into solid tumors. The development of CAR-T therapies in this space has primarily been impeded by the lack of novel cancer targets and targeting receptors and scalable and cost-effective manufacturing. The development of next generation T cell therapies, like the emerging TCR-T modality, are able to address these barriers to make personalized T cell immunotherapy scalable and accessible for solid tumor patients worldwide. Recent advances in high-throughput screening, genetic engineering, and automated manufacturing now enable systematic, end-to-end development workflows for targeted T cell therapies and it is evident that further innovation across the entire cell therapy development process is essential to transform extraordinary science into sustainable treatments capable of reaching patients everywhere.